Musso N R, Gianrossi R, Vergassola C, Pende A, Ioverno A, Galbariggi G, Lotti G
Department of Internal Medicine, University of Genoa, Italy.
J Hypertens. 1992 Sep;10(9):1017-23.
The purposes of this study were: (1) to test whether intravenous infusion of norepinephrine can affect plasma dopamine levels; and (2) to explore to what extent dopamine-2 or alpha 2-receptors play a role in this response.
Norepinephrine infusion in man was performed to test whether the increase in norepinephrine during sympathetic stimulation can affect dopamine release. Specific antagonists of presynaptic dopamine-2 and alpha 2-receptors were administered to test the receptor(s) involved in this possible regulatory phenomenon.
Plasma catecholamine levels were investigated in seven normal subjects before and after administration of domperidone (dopamine-2 antagonist), yohimbine (alpha 2-antagonist) and norepinephrine.
Both oral domperidone and yohimbine induced a significant increase in both plasma norepinephrine and plasma dopamine. Norepinephrine infusion induced a significant decrease in plasma dopamine. Pretreatment with domperidone only partially counteracted this inhibitory effect of norepinephrine infusion, whereas yohimbine fully counteracted it.
Our data show that norepinephrine may act as a hormone at plasma concentrations as low as 450 pg/ml. The norepinephrine-induced plasma dopamine decrease seems to be alpha 2-adrenoceptor-mediated. This norepinephrine effect may be involved in the physiologic decrease in plasma dopamine that we demonstrated in the upright position in normal subjects.
本研究的目的是:(1)测试静脉输注去甲肾上腺素是否会影响血浆多巴胺水平;(2)探究多巴胺2受体或α2受体在这一反应中发挥作用的程度。
对人体进行去甲肾上腺素输注,以测试交感神经刺激期间去甲肾上腺素的增加是否会影响多巴胺释放。给予突触前多巴胺2受体和α2受体的特异性拮抗剂,以测试参与这一可能调节现象的受体。
在7名正常受试者服用多潘立酮(多巴胺2拮抗剂)、育亨宾(α2拮抗剂)和去甲肾上腺素之前和之后,对其血浆儿茶酚胺水平进行研究。
口服多潘立酮和育亨宾均导致血浆去甲肾上腺素和血浆多巴胺显著增加。去甲肾上腺素输注导致血浆多巴胺显著降低。仅用多潘立酮预处理只能部分抵消去甲肾上腺素输注的这种抑制作用,而育亨宾则能完全抵消。
我们的数据表明,去甲肾上腺素在低至450 pg/ml的血浆浓度下可能作为一种激素起作用。去甲肾上腺素诱导的血浆多巴胺降低似乎是由α2肾上腺素能受体介导的。这种去甲肾上腺素效应可能与我们在正常受试者直立位时所证明的血浆多巴胺生理性降低有关。